The United States Food and Drug Administration's risk management framework

Drug Information Journal

Volumn 36, Issue 2, 2002, Pages 333-341

  Steidle, Gina ^a   Hodges, Shawn E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Data mining; FDA; MedWatch; Office of Postmarketing Drug Risk Assessment (OPDRA); Peter Honig; Risk management

Indexed keywords

CONFERENCE PAPER; CONSUMER; DRUG APPROVAL; DRUG INFORMATION; DRUG LABELING; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HEALTH EDUCATION; MEDICAL INFORMATION; PHILOSOPHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK MANAGEMENT; STAFF; STANDARD; UNITED STATES;

EID: 0036377812     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150203600212     Document Type: Conference Paper

References (21)

1. US Food and Drug Administration. Managing the Risks from Medical Product Use-Creating a Risk Management Framework. 1999. http://www.fda.gov/oc/tfrm/executivesummary.html.
2. Statement by Janet Woodcock, MD, Director, Center for Drug Evaluation and Research, before the Committee on Health, Education, Labor and Pensions, United States Senate, February 1, 2000.
3. Uhl K, Honig P. Risk management of marketed drugs: FDA and the interface with the practice of medicine. Pharmacoepidemiology Drug Safety. 2001;10:205-208.
4. Honig P. Update on the New FDA Office of Postmarketing Drug Risk Assessment (OPDRA). Presented at the Drug Information Association 1999 Annual Meeting. http://www.fda.gov/cder/present/dia-699/opdra2-dia/sld001.htm.
5. US Food and Drug Administration. Guidance for Reviewers: Pharmacology and Toxicology Review Format. 2001. http://www.fda.gov/cder/guidance/4120fnl.pdf.
6. US Food and Drug Administration. Reviewer Guidance-Conducting a Clinical Safety Review of a New Product. Rockville, MD: US Food and Drug Administration; November 22, 1996.
7. US Food and Drug Administration. Application and Preparing a Report of the Review. 1996. http.//www.fda.gov/cder/guidance/issrvg08.pdf.
8. Rarick L. The CDER 2001 Good Review Practices Initiative (Clinical). http://www.fda.gov/cder/present/dia72001/grpdia/sld001.htm.
9. US Food and Drug Administration. Guidance for Industry: Fast Track Drug Development Programs-Designation, Development, and Application Review. Rockville, MD: US Food and Drug Administration; September 1998.
10. Institute of Medicine. To Err is Human: Building a Safer Health System. Washington, DC: Institute of Medicine; 1999.
11. General Accounting Office. Adverse Drug Events-The Magnitude of Health Risk Is Uncertain Because of Limited Incidence Data. January 2000. http://www.gao.gov/archive/2000/he00021.pdf.
12. Lillie R. Update on the Office of Postmarketing Drug Risk Assessment (OPDRA). http://www.fda.gov. cder/present/ispe-1999/ispi2/sld001.htm.
13. General Accounting Office. Major Management Challenges and Program Risks-Department of Health and Human Services. January 2001. http://www.gao.gov.
14. US Food and Drug Administration. Update from the Office of Postmarketing Drug Risk Assessment. 2001. http://www.fda.gov/cder/present/dia-62000/opdra/sld00l.htm.
15. US Food and Drug Administration. Final Summary of Food and Drug Administration (FDA) Action Items-Doing What Counts for Patient Safety: Federal Actions to Reduce Medical Errors and Their Impact. 2001. http://www.fda.gov/cder/drug/mederrors/patientsafety.htm.
16. US Food and Drug Administration. Draft Guidance for Industry: Content and Format of the Adverse Reactions Section of Labeling for Human Prescription Drugs and Biologics. http://www.fda.gov/cder/guidance/1888dft.pdf.
17. Shiew-Mei Huang, Associate Director for FDA's Office of Clinical Pharmacology and Biopharmaceutics Science and Regulatory Policy. The Pink Sheet. January 3, 2000.
18. Reference to RAPS Annual Conference Session-Risk Management-Impact on the Consumer. Rockville Dispatch. October 6, 2000.
19. US Food and Drug Administration. Adverse Event Reporting System. http://www.fda.gov/cder/aers/default.htm.
20. Agency for Health Care Research and Quality. Centers for Education and Research on Therapeutics. http.//www.ahrq.gov/clinic/certsfact.pdf.
21. US Food and Drug Administration. CERTS and the FDA, Implementation of FDAMA 409. http://www.fda.gov/cder/present/dia-62000/certsd/sld001.htm.